A formulary analysis of angiotensin II antagonists in a UK teaching hospital

Disease Management and Health Outcomes

Volumn 10, Issue 6, 2002, Pages 355-362

  Moore, Andrew P ^a,b   Wheeldon, Nigel M ^a   Jennings, Mike ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; DRUG FORMULARY; DRUG SCREENING; SCORING SYSTEM; TEACHING HOSPITAL; UNITED KINGDOM;

EID: 0036291835     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210060-00005     Document Type: Article

References (80)

1. Losartan, a new type of antihypertensive
2. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion
3. ACE inhibitors and angiotensin II antagonists for the treatment of hypertension: Drug selection by means of the SOJA method
4. Angiotensin II antagonists in hypertension: Drug selection by means of the SOJA method
5. Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors
6. Improving the drug evaluation process
7. Teveten (eprosartan mesylate). Summary of product characteristics
8. Micardis (telmisartan). Summary of product characteristics
9. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
10. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension
11. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
12. 24-Hour blood pressure control by once daily administration of irbesartan assessed by ambulatory blood pressure monitoring
13. The efficacy and tolerance of one and two daily doses of eprosartan in essential hypertension
14. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension
15. Comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
16. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension
17. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study
18. Effects of Losartan and Candesartan monotherapy and Losartan/Hydrochlorothiazide combination therapy in patients with mild to moderate hypertension
19. Comparative efficacy of the two angiotensin II receptor antagonists, irbesartan and losartan, in mild to moderate hypertension
20. An elective titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan
21. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension
22. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and haemodynamics in patients with essential hypertension
23. Effects of losartan on hypertension and left ventricular mass: A long-term study
24. Correction of hypertensive cardiac remodelling: Comparison of different antihypertensive therapies
25. Long-term central haemodynamic effects at rest and during exercise of losartan in essential hypertension
26. Effects of valsartan and enalapril on regresssion of left ventricular hypertrophy in patients with mild to moderate hypertension: A randomized, double blind study
27. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
28. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
29. Effects of losartan on renal function in patients with essential hypertension
30. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study
31. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly patients with or without non-insulin-dependent diabetes mellitus
32. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile and microalbuminuria in hypertensive type 2 diabetic patients
33. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
34. Comparison of losartan and amlodipine in renally impaired hypertensive patients
35. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
36. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM
37. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics
38. Effect of losartan on TGF-(beta)1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria
39. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial
40. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
41. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
42. Antihypertensive effects of candesartan cilexetil, enalapril and placebo
43. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate hypertension - A population analysis
44. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population
45. Effects of candesartan cilexetil in patients with systemic hypertension
46. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension
47. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: A double-blind, placebo-controlled, dose titration study
48. Dose-related antihypertensive effect of irbesartan in patients with mild-to-moderate hypertension
49. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
50. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension
51. Randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension
52. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
53. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
54. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
55. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring
56. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension
57. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
58. Efficacy, tolerability and quality of life of losartan, alone or in combination with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension
59. Efficacy, tolerability and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
60. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension
61. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being
62. Comparative antihypertensive effects of losartan 50mg and losartan 50mg titrated to 100mg in patients with essential hypertension
63. Efficacy, safety, and effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension
64. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring
65. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension
66. A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension
67. Comparison of antihypertensive and metabolic effects of losartan in combination with hydrochlorothiazide - A randomized controlled trial
68. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension
69. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficay and safety compared to hydrochlorothiazide
70. Valsartan, a new angiotensin II antagonist: Efficacy and toterability compared with an angiotensin-converting enzyme inhibitor enalapril in essential hypertension
71. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
72. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril
73. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
74. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
75. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy
76. Angiotensin II antagonists for hypertension: Are there differences in efficacy?